Nanobiotix (NASDAQ:NBTX – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, Zacks.com reports.
According to Zacks, “Nanobiotix S.A. is a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer. The company’s proprietary technology includes NBTXR3. Nanobiotix S.A. is headquartered in Paris, France. “
NASDAQ NBTX opened at $5.01 on Friday. Nanobiotix has a twelve month low of $4.65 and a twelve month high of $18.00. The stock has a fifty day simple moving average of $6.32 and a 200-day simple moving average of $7.52.
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Nanobiotix (NBTX)
- Should Dollar General or Dollar Tree Give Investors a Case of FOMO?
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
- Beware The Rebound In Retail Stocks
- It’s A Good Time To Own Ralph Lauren (NYSE: RL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.